(Q47855368)

6 February 2018

http://europepmc.org/abstract/MED/28872677

title

Immunogenicity assessment during the development of protein therapeutics (English)

1 reference

6 February 2018

http://europepmc.org/abstract/MED/28872677

author

Zuben E Sauna

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28872677%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Amy S Rosenberg

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28872677%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

5 September 2017

1 reference

6 February 2018

http://europepmc.org/abstract/MED/28872677

published in

Journal of Pharmacy and Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28872677%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28872677%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28872677%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

584-594

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28872677%20AND%20SRC:MED&resulttype=core&format=json

Recent advances in (therapeutic protein) drug development.

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Building better drugs: developing and regulating engineered therapeutic proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Scientific and regulatory considerations on the immunogenicity of biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Biopharmaceutical benchmarks 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Fc fusion as a platform technology: potential for modulating immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Subvisible Particle Content, Formulation, and Dose of an Erythropoietin Peptide Mimetic Product Are Associated With Severe Adverse Postmarketing Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Naive and memory B cells in T-cell-dependent and T-independent responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Control systems and decision making for antibody production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Immunodominance of CD4 T cells to foreign antigens is peptide intrinsic and independent of molecular context: implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

The MHC class I antigen presentation pathway: strategies for viral immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

An algorithm for the prediction of proteasomal cleavages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Two-step binding mechanism for T-cell receptor recognition of peptide MHC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Functional recombinant MHC class II molecules and high-throughput peptide-binding assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Immunology by numbers: quantitation of antigen presentation completes the quantitative milieu of systems immunology!

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

A Systems Approach to Understand Antigen Presentation and the Immune Response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Sizing up the key determinants of the CD8(+) T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Methods to measure T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Conditional modeling of antibody titers using a zero-inflated poisson random effects model: application to Fabrazyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

ImmunoGrid: towards agent-based simulations of the human immune system at a natural scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

Development of immune-specific interaction potentials and their application in the multi-agent-system VaccImm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

The Basic Immune Simulator: an agent-based model to study the interactions between innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1-theoretical model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2-model applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12810

21 January 2018

Identifiers

DOI

10.1111/JPHP.12810

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28872677%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference